Search or
𝛼SK
𝛼SKbullish
CHMP Meeting Update: Eight New Medicines Recommended For Approval
425 Views03 Feb 2025 08:30
SUMMARY
- In its January 2025 meeting, EMA’s human medicines committee (CHMP) recommended eight medicines for approval, including four innovative, three biosimilars, and one generic drugs.
- The committee has also recommended extensions of indication for eight medicines that are already authorized in the EU.
- Marketing applications for two medicines were withdrawn. Among them, withdrawal of Daiichi Sankyo’s datopotamab deruxtecan for non-squamous non-small cell lung cancer is noteworthy.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
- CHMP Meeting Update April 2025: Sixteen New Medicines Recommended For Approval27 Apr 2025
- CHMP Meeting Update: Five New Medicines Recommended for Approval, Rejects Kisunla Application01 Apr 2025
- CHMP Meeting Update: 4 New Medicines Recommended For Approval, Reinstates Previous Leqembi Decision03 Mar 2025
x